| Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies I Verbrugge, J Hagekyriakou, LL Sharp, M Galli, A West, NM McLaughlin, ... Cancer research 72 (13), 3163-3174, 2012 | 285 | 2012 |
| Combination approaches with immune-checkpoint blockade in cancer therapy M Swart, I Verbrugge, JB Beltman Frontiers in oncology 6, 233, 2016 | 158 | 2016 |
| Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma MA Deken, J Gadiot, ES Jordanova, R Lacroix, M van Gool, P Kroon, ... Oncoimmunology 5 (12), e1238557, 2016 | 139 | 2016 |
| Differentiation therapy for the treatment of t (8; 21) acute myeloid leukemia using histone deacetylase inhibitors M Bots, I Verbrugge, BP Martin, JM Salmon, M Ghisi, A Baker, K Stanley, ... Blood, The Journal of the American Society of Hematology 123 (9), 1341-1352, 2014 | 129 | 2014 |
| The CDK9 inhibitor dinaciclib exerts potent apoptotic and antitumor effects in preclinical models of MLL-rearranged acute myeloid leukemia A Baker, GP Gregory, I Verbrugge, L Kats, JJ Hilton, E Vidacs, EM Lee, ... Cancer research 76 (5), 1158-1169, 2016 | 113 | 2016 |
| SnapShot: extrinsic apoptosis pathways I Verbrugge, RW Johnstone, MJ Smyth Cell 143 (7), 1192-1192. e2, 2010 | 93 | 2010 |
| Ubiquitination by the Membrane-associated RING-CH-8 (MARCH-8) Ligase Controls Steady-state Cell Surface Expression of Tumor Necrosis Factor-related Apoptosis Inducing Ligand … B van de Kooij, I Verbrugge, E de Vries, M Gijsen, V Montserrat, C Maas, ... Journal of Biological Chemistry 288 (9), 6617-6628, 2013 | 88 | 2013 |
| Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population N Hein, DP Cameron, KM Hannan, NYN Nguyen, CY Fong, J Sornkom, ... Blood, The Journal of the American Society of Hematology 129 (21), 2882-2895, 2017 | 84 | 2017 |
| Ionizing radiation modulates the TRAIL death-inducing signaling complex, allowing bypass of the mitochondrial apoptosis pathway I Verbrugge, E De Vries, SWG Tait, EHJ Wissink, H Walczak, M Verheij, ... Oncogene 27 (5), 574-584, 2008 | 57 | 2008 |
| TRAIL enhances efficacy of radiotherapy in a p53 mutant, Bcl-2 overexpressing lymphoid malignancy EHJ Wissink, I Verbrugge, SR Vink, MB Schader, U Schaefer, H Walczak, ... Radiotherapy and Oncology 80 (2), 214-222, 2006 | 57 | 2006 |
| Smac/DIABLO release from mitochondria and XIAP inhibition are essential to limit clonogenicity of Type I tumor cells after TRAIL receptor stimulation C Maas, I Verbrugge, E de Vries, G Savich, LW Van de Kooij, SWG Tait, ... Cell Death & Differentiation 17 (10), 1613-1623, 2010 | 55 | 2010 |
| Combining radiotherapy with APO010 in cancer treatment I Verbrugge, EHJ Wissink, RW Rooswinkel, J Jongsma, N Beltraminelli, ... Clinical Cancer Research 15 (6), 2031-2038, 2009 | 46 | 2009 |
| Radiotherapy and cisplatin increase immunotherapy efficacy by enabling local and systemic intratumoral T-cell activity P Kroon, E Frijlink, V Iglesias-Guimarais, A Volkov, MM van Buuren, ... Cancer Immunology Research 7 (4), 670-682, 2019 | 44 | 2019 |
| Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma P Kroon, J Gadiot, M Peeters, A Gasparini, MA Deken, H Yagita, M Verheij, ... Cancer Immunology, Immunotherapy 65, 753-763, 2016 | 43 | 2016 |
| Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8+ T cells E Matas-Rico, E Frijlink, I van der Haar Àvila, A Menegakis, M van Zon, ... Cell reports 37 (7), 2021 | 42 | 2021 |
| The curative outcome of radioimmunotherapy in a mouse breast cancer model relies on mTOR signaling I Verbrugge, A Gasparini, NM Haynes, J Hagekyriakou, M Galli, ... Radiation research 182 (2), 219-229, 2014 | 33 | 2014 |
| Radiation and anticancer drugs can facilitate mitochondrial bypass by CD95/Fas via c-FLIP downregulation I Verbrugge, C Maas, M Heijkoop, M Verheij, J Borst Cell Death & Differentiation 17 (3), 551-561, 2010 | 31 | 2010 |
| Promises and challenges of anticancer drugs that target the epigenome I Verbrugge, RW Johnstone, M Bots Epigenomics 3 (5), 547-565, 2011 | 26 | 2011 |
| Stem cell-derived cardiomyocytes after bone marrow and heart transplantation RA De Weger, I Verbrugge, AH Bruggink, MM Van Oosterhout, ... Bone marrow transplantation 41 (6), 563-569, 2007 | 24 | 2007 |
| Enhancing the antitumor effects of radiotherapy with combinations of immunostimulatory antibodies I Verbrugge, M Galli, MJ Smyth, RW Johnstone, NM Haynes Oncoimmunology 1 (9), 1629-1631, 2012 | 13 | 2012 |
